AcelRx stock plunges after FDA rejects pain drug device
July 28, 2014 at 08:48 AM EDT
July 28 (Reuters) - Shares of AcelRx Pharmaceuticals Inc plunged nearly 28 percent in premarket trading, after the U.S. Food and Drug Administration rejected its pain drug device, Zalviso, late on Friday.
